Table 1.
Subject demographics and treatment information.
| CD |
UC |
Non-IBD |
||||
|---|---|---|---|---|---|---|
| Cohort | STL | CBG | STL | CBG | STL | CBG |
| Number of patients | 30 | 3 | 14 | 11 | 30 | 9 |
| Number of specimens | 62 | 8 | 26 | 26 | 30 | 11 |
| % Male | 33.3 | 33.3 | 57.1 | 63.6 | 33.3 | 55.5 |
| Age | 43.2 ± 14.8 | 46.0 ± 11.0 | 49.9 ±15.5 | 38.5 ± 14.2 | 50 ± 15.5 | 44.9 ± 11.6 |
| BMI (n) | 25.7 ± 5.5 (28) | NA | 29.2 ± 7.4## (14) | NA | 23.6 ± 5.2 (29) |
NA |
| Race | 100 | 100 | 100 | |||
| % Caucasian | 93.3 ** | 92.9 | 66.7 | |||
| % African American | 6.7 | 7.2 | 20.0 | |||
| % Other | 0.0 ** | 0.0 | 13.3 | |||
| Longitudinal (n) | 20 | 1 | 6 | 6 | 0 | 1 |
| Treatment# | ||||||
| % Steroids (oral/IV) | 26.7 | 66.7 | 20 | 72.7 | 0 | 0 |
| % Vedolizumab | 43.3 | 0 | 16.7 | 0 | 0 | 0 |
| % TNFα inhibitors | 36.7 | 0 | 10 | 0 | 0 | 0 |
| % 5-ASAs | 30 | 0 | 43.3 | 90.9 | 0 | 0 |
| % Purine analogs | 43.3 | 33.3 | 16.7 | 36.4 | 0 | 0 |
| % Other immunomod^ | 10 | 33.3 | 16.7 | 27.3 | 0 | 0 |
| % Antibiotics | 13.3 | 33.3 | 3.3 | 9.4 | 7.2 | 0 |
Date presented as ± mean.
#Treatment information for the second sample collected for subjects with longitudinal sampling. **CD vs Non-IBD; ##UC vs Non-IBD